Oncogenes and cancer.

  title={Oncogenes and cancer.},
  author={Carlo Maria Croce},
  journal={The New England journal of medicine},
  volume={358 5},
  • C. Croce
  • Published 31 January 2008
  • Biology, Medicine, Chemistry
  • The New England journal of medicine
This review — the first in a series concerning the biology of cancer — is a comprehensive survey of oncogenes, tumor-suppressor genes, and microRNA genes in cancer cells. Work on the recently discovered microRNA genes in malignant cells has revealed new complexities in the regulation of oncogenes and tumor-suppressor genes and new opportunities for the treatment of cancer. 

Figures and Tables from this paper

Oncogenes as Therapeutic Targets in Cancer: A Review
An overview of the functions, properties and clinical importance of oncogenes is discussed in this review.
Oncogenes - the basics
Normal cell cycle and cell proliferation are regulated by several genes which can be broadly classified into 4 groups viz, proto-oncogenes, tumor suppressor genes, genes regulating apoptosis and
Oncomirs: from tumor biology to molecularly targeted anticancer strategies.
An overview of miRNA biology is provided, the most recent findings on miRNA and cancer development/progression are discussed, and how tumor-related miRNAs (oncomirs) are being used to develop novel cancer specific therapeutic approaches are reported on.
Viral and Nonviral Oncogene Theories of Cancer
The span of medical and molecular biology research in the field of oncology during the last six decades is surveyed, finding that cancer is a multiplicity of different disorders that appear to arise through nonviral auto-oncogenic processes involving adaptive changes and epigenetic responses to cancer-promoting pressures in the external and internal environment of the organism.
Principles of Cancer Pathogenesis and Therapies: A Brief Overview
Scientific and technological advances in all areas of oncology enable earlier and more accurate diagnoses, which improve treatment in cancer patients, and new classes of anticancer agents have contributed to improved cancer therapies.
Neoplasia from genetic point of view.
The cancer genetics is discussed from different aspects and knowing the mechanism of molecular and cytogenetic alterations in cancer will give an advantage in finding more practical approaches to cancer management.
Molecular Mechanism of Carcinogenesis
The genes involved in cell cycle control, apoptosis, DNA repair, aging and immortalization, angiogenesis, and metastasis play a significant role in cancer.
Nuclear Oncology 1: Principles of Tumor Pathology and Biology
This chapter will deal with the pathological basis of tumorigenesis and the basic principles of pathological classification of tumors.
Genes responsible for cancer: a review
The discovery of the involvement of microRNAs in the initiation and progression of human cancer may provide additional targets for anticancer treatments.
P53-binding protein 1: a new player for tumorigenesis and a new target for breast cancer treatment.


Recently, many cellular oncogenes were identified in human cancerous cells by the DNA transfection method, some of which were found to contain sequences related with already known viral oncogenees.
MicroRNA signatures in human cancers
MiRNA-expression profiling of human tumours has identified signatures associated with diagnosis, staging, progression, prognosis and response to treatment and has been exploited to identify miRNA genes that might represent downstream targets of activated oncogenic pathways, or that target protein-coding genes involved in cancer.
ras and human tumors.
Mutational activation of ras oncogenes is frequently encountered in human tumors, but in lung cancer, childhood lymphoblastic leukemia and possibly in myelodysplastic syndromes ras mutations may predict a poor prognosis.
Molecular abnormalities in lung cancer.
  • R. Salgia, A. Skarin
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
The identified molecular abnormalities in lung cancer are currently used to develop diagnostics for detecting early disease, as well as to identify targets for gene therapy, to develop novel investigational approaches to the treatment of lung cancer.
RAS and leukemia: from basic mechanisms to gene-directed therapy.
  • D. Beaupre, R. Kurzrock
  • Biology, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
An increasing body of data suggests that disruption of Ras signaling pathways, either directly through mutations or indirectly through other genetic aberrations, is important in the pathogenesis of a wide variety of cancers.
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
A landmark was the discover that chronic myeloid leukemia, probably the first type of leukemia to be recognized, in the 1840s, as a distinct entity, can be treated with chemotherapy.
Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue
DNA sequence analysis of the activated oncogene from the T24 human bladder carcinoma line and two alleles of its normal cellular progenitor (c-Ha-ras-1) indicates that the genes encompass at least
Mutations of the BRAF gene in human cancer
BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers, with a single substitution (V599E) accounting for 80%.